Joint Clinical Trials Office
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia or High-risk myelodysplasia
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Phase II study of Polatuzumab vedotin in combination with chemotherapy in subjects with Richter’s Transformation
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated with H. pylori Infection and Gastric Cancer Carcinogenesis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Liquid Biopsy for Longitudinal Monitoring in Diffuse Midline Glioma (DMG) Patients
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Comparison of Venipuncture Serum Prostate Specific Antigen (PSA) with Point of Care Fingerstick Blood Draw Rapid Test for PSA (RT-PSA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib Who Have Received Prior Anti-Androgen Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023